Just one dose of 'magic mushroom' compound was given to cancer patients, the long-term results shocked researchers

A new study has found that a single dose of psilocybin, the active compound in magic mushrooms, could help cancer patients suffering from depression and anxiety. The study shows that just one dose, when combined with therapy, gave long-lasting relief, with effects seen even after two years.

The results were published by Wiley in Cancer, a journal of the American Cancer Society.

People with cancer often experience serious emotional distress. In this phase 2 trial, 28 cancer patients diagnosed with major depression were given support from therapists before, during, and after taking a single 25-mg dose of psilocybin.

After two years, interviews showed that 15 patients (around 54%) had a strong reduction in their depression symptoms. Fourteen patients (50%) had both a drop in depression and went into remission. Anxiety levels also improved in 12 patients (about 43%).

A new, larger study is now underway. It is a randomised, double-blind trial testing up to two doses of psilocybin against a placebo to see if more patients can achieve full recovery from depression and anxiety.

Dr. Manish Agrawal of Sunstone Therapies, the lead author, said, “One dose of psilocybin with support can ease depression for up to two years in many cancer patients. We’re now studying if more doses can help even more people.”

Researchers hope that, if future trials confirm these findings, psilocybin, used alongside therapy, could become a regular treatment for cancer patients dealing with depression and anxiety.

Inputs from agencies